- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02943057
Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis
Intra-cameral Penetration and Efficacy of Ganciclovir Following Topical Administration of 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis
25 patients who are diagnosed with Cytomegalovirus (CMV) anterior segment infection, either uveitis or endotheliitis, will be started on 2% guttae ganciclovir, 1 drop 5 times a day for 6 weeks.
Following 6 weeks of continuous application of 2% guttae ganciclovir, patient will be reviewed at the clinic within 3 hours following the last application of topical ganciclovir and clinical features will be documented for activity assessment. An aqueous sample 0.2ml is drawn. 0.1ml will be sent for RT-PCR for CMV viral load and another 0.1ml will be sent for ganciclovir drug level by HPLC method.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is non-randomised single armed prospective, cross-sectional, interventional clinical study.
25 patients who are diagnosed with Cytomegalovirus (CMV) anterior segment infection, either uveitis or endotheliitis, at the investigators clinic in Singapore National Eye Centre, who have a positive aqueous real time PCR (RT-PCR) and/or positive tetraplex PCR for CMV and have not had any form of ganciclovir treatment in the past 1 month, will be recruited in the study after taking an informed consent. This will also include the patients who have never been treated with antiviral therapy and those with recurrent disease and have not had any form of ganciclovir treatment for past 1 month.
The clinical features of the active disease will be recorded in the data collection sheet and will include, documentation of the state of the cornea, KPs, AC cells, flare, flare meter reading (where possible), central corneal thickness, Intra ocular pressure (IOP) and C:D ratio.
All patients will be started on 2% guttae ganciclovir, 1 drop 5 times a day.
2% Guttae ganciclovir will be prepared from vials of ganciclovir powder for ganciclovir intravenous infusion using aseptic method.
Following 6 weeks of continuous application of 2% guttae ganciclovir, patient will be reviewed at the clinic within 3 hours following the last application of topical ganciclovir.
- Clinical features mentioned above will be documented for activity assessment
- Following irrigation of the conjunctival sac with 100ml of N/S to wash out any residual drug, aseptic technique is practised before an aqueous sample 0.2ml is drawn. 0.1ml will be sent for RT-PCR for CMV viral load and another 0.1ml will be sent for ganciclovir drug level by HPLC method.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Samanthila Waduthantri
- Phone Number: 63228855
- Email: samanthila.waduthatri@snec.com.sg
Study Locations
-
-
-
Singapore, Singapore
- Singapore National Eye Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age between 21 and above
- Patients who are diagnosed with anterior uveitis or endotheliitis with a positive aqueous real time PCR (RT-PCR) and/or positive tetraplex PCR for Cytomegalovirus (CMV)
- Patients with relapses and recurrent anterior segment disease that is PCR positive for CMV in aqueous
- Have not been on any form of (topical, local or systemic) ganciclovir therapy for the past 1 month
- Consent to undergo anterior chamber tap and give aqueous and tear samples for the study
- Able to undergo relevant tests (e.g. laser flare cell photometry)
- Able to come for subsequent follow-up visits
- Ability to provide informed consent
Exclusion Criteria:
- CMV anterior uveitis with associated retinitis
- Other causes of hypertensive anterior uveitis / endotheliitis such as HSV, VZV infection
- Patients who have been on any form of (topical, local or systemic) ganciclovir therapy for the past1 month.
- Patients who are allergic to ganciclovir
- Patients who will require systemic or intra-vitreal ganciclovir therapy
- Immunocompromised patients
- Positive for HIV, Hep B and Hep C
- Not keen on participating in the study
- Patients who are incapable, either by law or mental state, of giving consents in their own right.
- Patients who are either unable or unwilling to keep scheduled appointments and adhere to the other aspects of the protocol
- Patients who are pregnant or breastfeeding
- Any other specified reason as determined by the clinical investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 2% guttae Ganciclovir
2% guttae Ganciclovir 5 times a day for 6 weeks
|
2% guttae ganciclovir 5 times a day for 6 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median concentration of ganciclovir in aqueous by HPLC-Mass spectrometry end of week 6
Time Frame: 6 weeks
|
Ganciclovir concentration in aqueous will be measured by HPLC-Mass spectrometry at the end of week 6
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical efficacy in clearing CMV viral load and resolution of anterior uveitis/endotheliitis following 6 weeks of treatment
Time Frame: 6 weeks
|
Clinical efficacy will be measured by resolution of anterior uveitis/ endotheliitis and aqueous tap negative for CMV realtime PCR at the end of week 6
|
6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: SP Chee, Singapre national eye centre
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Virus Diseases
- Infections
- Eye Diseases
- DNA Virus Infections
- Panuveitis
- Uveal Diseases
- Herpesviridae Infections
- Iris Diseases
- Cytomegalovirus Infections
- Uveitis
- Uveitis, Anterior
- Iridocyclitis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Ganciclovir
- Ganciclovir triphosphate
Other Study ID Numbers
- R1226/32/2015
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cytomegalovirus Infections
-
University of Alabama at BirminghamEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingMaternal Cytomegalovirus Infections | Cytomegalovirus CongenitalUnited States
-
University of Sao Paulo General HospitalCompletedCytomegalovirus DiseaseBrazil
-
Mayo ClinicCompletedCytomegalovirus InfectionUnited States
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus InfectionUnited States, France, Germany, Italy, Japan, United Kingdom
-
Assistance Publique - Hôpitaux de ParisCompletedCongenital Cytomegalovirus InfectionFrance
-
National Institute of Allergy and Infectious Diseases...Terminated
-
Institut PasteurCompletedCongenital Cytomegalovirus InfectionFrance
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus (CMV) InfectionsUnited States, Australia, Canada, Finland, Israel, Russian Federation, Spain
-
Assistance Publique - Hôpitaux de ParisCompletedCongenital Cytomegalovirus InfectionFrance
-
The George Washington University Biostatistics...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedCongenital Cytomegalovirus Infection | Maternal Cytomegalovirus InfectionUnited States
Clinical Trials on 2% guttae ganciclovir
-
Peking University People's HospitalUnknownCytomegalovirus Infections
-
Tianjin Medical UniversityRecruitingCytomegalovirus Retinitis | Ganciclovir Eye DropsChina
-
National Institute of Allergy and Infectious Diseases...Completed
-
Johns Hopkins Bloomberg School of Public HealthCompletedHIV Infections | Cytomegalovirus RetinitisUnited States
-
University of Oslo School of PharmacyTerminatedAcute Renal Failure | Cytomegalovirus Infections | Multi Organ FailureNorway
-
National Center for Research Resources (NCRR)UnknownCytomegalovirus InfectionsUnited States
-
National Center for Research Resources (NCRR)National Institute of Allergy and Infectious Diseases (NIAID)CompletedCytomegalovirus Infections
-
University of Alabama at BirminghamNational Cancer Institute (NCI)Completed
-
Salvador Gil-VernetRoche Pharma AGCompletedCytomegalovirus InfectionSpain
-
Fred Hutchinson Cancer CenterNational Heart, Lung, and Blood Institute (NHLBI); Genentech, Inc.CompletedRespiratory Failure | Acute Respiratory Distress Syndrome | Acute Lung InjuryUnited States